Main outcomes
| . | All patients (N = 213) . | WHO-ET (n = 178) . | Early PMF (n = 35) . | P . |
|---|---|---|---|---|
| Median follow-up, y (range) | 7.6 (0-27) | 7.6 (0-27) | 7.4 (0-27) | .976 |
| Cytoreductive therapy, n (%) | 78 (37) | 63 (35) | 15 (43) | .459 |
| Aspirin, n (%) | 137 (64) | 111 (62) | 26 (74) | .178 |
| Thrombosis during follow-up, n (%) | 16 (8) | 11 (6) | 5 (14) | .096 |
| Rate, % pts/y (95% CI) | 0.84 (0.50-1.39) | 0.74 (0.41-1.34) | 1.30 (0.49-3.47) | .326 |
| Arterial, n (%) | 11 (5) | 7 (4) | 4 (11) | .086 |
| Rate, % pts/y (95% CI) | 0.54 (0.29-1.01) | 0.46 (0.22-0.96) | 0.97 (0.31-0.31) | .284 |
| Venous, n (%) | 7 (3) | 5 (3) | 2 (6) | .323 |
| Rate, % pts/y (95% CI) | 0.38 (0.18-0.79) | 0.33 (0.14-0.79) | 0.59 (0.15-0.36) | .462 |
| Hemorrhages, n (%) | 11 (5) | 8 (5) | 3 (9) | .390 |
| Rate, % pts/y (95% CI) | 0.53 (0.28-0.98) | 0.45 (0.22-0.95) | 0.88 (0.28-2.71) | .281 |
| Evolutions in MF, n (%) | 7 (3) | 4 (3) | 3 (9) | .106 |
| Rate, % pts/y (95% CI) | 0.38 (0.18-0.80) | 0.26 (0.10-0.70) | 0.94 (0.30-2.94) | .069 |
| Evolutions in AL, n (%) | 0 (0) | 0 (0) | 0 (0) | - |
| Rate, % pts/y (95% CI) | 0 (0) | 0 (0) | 0 (0) | - |
| Deaths, n (%) | 0 (0) | 0 (0) | 0 (0) | - |
| Rate, % pts/y (95% CI) | 0 (0) | 0 (0) | 0 (0) | - |
| All events, n (%)* | 31 (15) | 20 (11) | 11 (31) | .002 |
| Rate, % pts/y (95% CI) | 2.76 (2.37-3.21) | 1.29 (0.82-2.03) | 3.43 (1.85-6.37) | .010 |
| . | All patients (N = 213) . | WHO-ET (n = 178) . | Early PMF (n = 35) . | P . |
|---|---|---|---|---|
| Median follow-up, y (range) | 7.6 (0-27) | 7.6 (0-27) | 7.4 (0-27) | .976 |
| Cytoreductive therapy, n (%) | 78 (37) | 63 (35) | 15 (43) | .459 |
| Aspirin, n (%) | 137 (64) | 111 (62) | 26 (74) | .178 |
| Thrombosis during follow-up, n (%) | 16 (8) | 11 (6) | 5 (14) | .096 |
| Rate, % pts/y (95% CI) | 0.84 (0.50-1.39) | 0.74 (0.41-1.34) | 1.30 (0.49-3.47) | .326 |
| Arterial, n (%) | 11 (5) | 7 (4) | 4 (11) | .086 |
| Rate, % pts/y (95% CI) | 0.54 (0.29-1.01) | 0.46 (0.22-0.96) | 0.97 (0.31-0.31) | .284 |
| Venous, n (%) | 7 (3) | 5 (3) | 2 (6) | .323 |
| Rate, % pts/y (95% CI) | 0.38 (0.18-0.79) | 0.33 (0.14-0.79) | 0.59 (0.15-0.36) | .462 |
| Hemorrhages, n (%) | 11 (5) | 8 (5) | 3 (9) | .390 |
| Rate, % pts/y (95% CI) | 0.53 (0.28-0.98) | 0.45 (0.22-0.95) | 0.88 (0.28-2.71) | .281 |
| Evolutions in MF, n (%) | 7 (3) | 4 (3) | 3 (9) | .106 |
| Rate, % pts/y (95% CI) | 0.38 (0.18-0.80) | 0.26 (0.10-0.70) | 0.94 (0.30-2.94) | .069 |
| Evolutions in AL, n (%) | 0 (0) | 0 (0) | 0 (0) | - |
| Rate, % pts/y (95% CI) | 0 (0) | 0 (0) | 0 (0) | - |
| Deaths, n (%) | 0 (0) | 0 (0) | 0 (0) | - |
| Rate, % pts/y (95% CI) | 0 (0) | 0 (0) | 0 (0) | - |
| All events, n (%)* | 31 (15) | 20 (11) | 11 (31) | .002 |
| Rate, % pts/y (95% CI) | 2.76 (2.37-3.21) | 1.29 (0.82-2.03) | 3.43 (1.85-6.37) | .010 |
Thrombosis, hemorrhage, or evolution in MF, whichever occurred first.